Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination
|
Design
|
Case report
|
Case Presentation
|
Demographic and Clinical Characteristics of 7 Cases of Symptomatic Myocarditis After Dose 2 of Pfizer-BioNTech COVID-19 Vaccine |
|
Patient 1
|
Patient 2
|
Patient 3 |
Patient 4 |
Patient 5 |
Patient 6 |
Patient 7 |
Age, years
|
16 |
19 |
17 |
18 |
17 |
16 |
14 |
Sex
|
Male |
Male |
Male |
Male |
Male |
Male |
Male |
Race
|
White |
White |
White |
White |
White |
White |
White |
Weight, kg
|
68 |
68 |
71 |
69 |
64 |
71 |
92 |
Exposure to COVID-19 in 14 d before illness onset |
None |
None |
None |
None |
None |
None |
None |
Time between vaccine dose 2 and symptoms onset, days |
2 |
3 |
2 |
2 |
4 |
3 |
2 |
Total hospital LOS, days |
6 |
2 |
2 |
4 |
5 |
3 |
4 |
ICU LOS, days |
4 |
None |
None |
4 |
5 |
2 |
2 |
Symptoms on presentation |
Chest pain |
Present |
Present |
Present |
Present |
Present |
Present |
Present |
Other pain |
Bilateral arm pain |
Myalgia |
Bilateral arm pain, numbness, paresthesia |
-- |
Bilateral arm pain, abdominal pain |
-- |
-- |
Fever |
38.3C by history |
Subjective, chills |
-- |
Subjective |
Subjective |
-- |
38.3C by history |
Fatigue |
Present |
Present |
-- |
Present |
-- |
-- |
-- |
Other |
Nausea, vomiting, anorexia, headache |
Weakness |
-- |
Nausea |
Nausea, vomiting, anorexia, SOB, palpitations |
SOB |
SOB |
Summary of Diagnostics and Therapeutics: 7 Cases of Symptomatic Myocarditis After Dose 2 of Pfizer-BioNTech COVID-19 Vaccine |
Laboratory findings on admission: |
Troponin (normal range), ng/mL |
Troponin I: 2.59 (<0.03) |
High-sensitivity troponin T: 232 (<14) |
Troponin I: 5.55 (<0.045) |
Troponin T:1.09 (<0.01) |
Troponin T: 3.2 (<0.01) |
Troponin T: 0.66 (<0.01) |
Troponin I: 22.1 (<0.045) |
Brain natriuretic peptide (normal < 100), pg/mL |
-- |
-- |
-- |
-- |
-- |
-- |
107.9 |
NT-proBNP (normal <125), pg/mL |
428 |
-- |
376 |
-- |
978 |
149 |
-- |
Peripheral white blood cell count, thousands of cells per mm3 |
6.97 |
8.69 |
11.8 |
12.6 |
16.3 |
5.0 |
8.11 |
Absolute lymphocyte count, thousands of cells per mm3 |
1.69 |
1.39 |
2.13 |
2.3 |
4.1 |
1.4 |
1.05 |
Absolute neutrophil count, thousands of cells per mm3 |
4.65 |
5.93 |
7.46 |
9.5 |
9.8 |
2.8 |
4.73 |
Platelet count, thousands of cells per mm3 |
198 |
208 |
231 |
236 |
297 |
189 |
208 |
Albumin (g/dL) |
3.9 |
4.1 |
4.1 |
4.4 |
4.0 |
3.8 |
3.5 |
Aspartate transaminase, U/L |
54 |
29 |
41 |
82 |
150 |
59 |
87 |
Alanine transaminase, U/ |
30 |
14 |
33 |
20 |
46 |
22 |
38 |
Ferritin, ug/L |
70 |
-- |
90 |
103 |
347 |
65 |
84 |
CRP (normal <1.0), mg/dL |
0.99 |
6.7 |
2.5 |
12.7 |
18.1 |
1.5 |
7.7 |
ESR, mm/h |
18 |
13 |
6 |
40 |
38 |
3 |
10 |
Prothrombin time, seconds |
-- |
-- |
14.0 |
-- |
12.1 |
11.4 |
14.8 |
Partial thromboplastin time, seconds |
22.3 |
-- |
31.4 |
-- |
30.4 |
27.9 |
35.6 |
International normalized ratio INR |
1.11 |
-- |
1.06 |
-- |
1.13 |
1.06 |
1.2 |
Other pertinent laboratory findings: |
Highest troponin (normal range), ng/mL |
Troponin I: 12.43 (<0.80) |
High-sensitivity troponin T: 388 (<14) |
Troponin I: 12.20 (<0.045) |
Troponin T: 1.09 (<0.01) |
Troponin T: 3.33 (<0.01) |
Troponin T: 0.82 (<0.01) |
Troponin I: 22.1 (<0.045) |
Lowest troponin before discharge (normal range), ng/mL |
Troponin I: 1.42(<0.80) |
-- |
Troponin I: 5.79 (<0.045 |
Troponin T: 0.4 (<0.01) |
Troponin T: 0.96 (<0.01) |
Troponin T: 0.01 (<0.01) |
Troponin I: 8.02 (<0.045) |
Highest BNP (normal range), pg/mL |
-- |
-- |
-- |
-- |
-- |
-- |
205 (<100) |
Highest NT-proBNP (normal range) |
482 pg/mL (<125) |
-- |
376 pg/mL (<300) |
-- |
978 pg/mL (<125) |
275 pg/mL (<125) |
-- |
Highest CRP (normal <1.0), mg/dL |
1.23 |
6.7 |
2.53 |
12.7 |
18.1 |
1.8 |
12.7 |
COVID-19 PCR result |
Negative |
Negative |
Negative |
Negative |
Negative |
Negative |
Negative |
COVID-19 spike antibody (manufacturer) |
-- |
-- |
Positive (Roche) |
Positive (Roche) |
Positive (Roche) |
Positive (Roche) |
-- |
COVID-19 nucleocapsid antibody result (manufacturer) |
Negative (Abbott) |
-- |
Negative (Roche) |
Negative (Roche) |
Negative (Roche) |
Negative (Roche) |
Negative (Abbott) |
Respiratory pathogen panel PCR result (manufacturer) |
Negative (BioFire) |
Negative (BioFire) |
Negative (BioFire) |
Negative (BioFire) |
Negative (BioFire) |
Negative (BioFire) |
Negative (BioFire) |
Adenovirus diagnostics result |
Negative serum PCR |
-- |
Negative serology |
Negative serum PCR |
Negative serum PCR |
-- |
Negative serum PCR |
Enterovirus diagnostics result |
Negative serum PCR |
-- |
Negative serology |
Negative serum PCR |
Negative serum PCR |
Negative serum PCR |
Negative serum PCR |
Cytomegalovirus diagnostics result |
Negative serum PCR |
-- |
Negative serology |
Negative serum PCR |
Negative serum PCR |
Negative serum PCR |
Negative serology |
Epstein-Barr virus diagnostics result |
|
|
Negative serology |
Negative serum PCR |
Negative serum PCR |
Negative IgM, positive IgG antibody |
Negative serology |
Other diagnostics |
|
|
Negative parvovirus, bartonella, and Lyme serology, negative urine drug screen |
-- |
Negative parvovirus and bartonella serology, negative HHV-6 serum PCR |
Negative Lyme serology, negative mycoplasma serum PCR, negative parvovirus serum PCR |
Negative parvovirus IgM, positive parvovirus IgG antibody, negative mycoplasma PCR (throat swab) |
Diagnostic imaging findings: |
Cardiac MRI |
LGE (subepicardial) involving lateral LV apex, myocardial edema of lateral LV wall, left axillary adenopathy |
LGE involving mid LV wall, myocardial edema of basal inferolateral LV wall |
LGE (subepicardial) involving basal anterolateral and basal to midventricular inferolateral LV segments, myocardial edema, elevated extracellular volume fraction (29.2%) |
Fibrosis, myocardial edema, hyperemia, mild mitral regurgitation (RF ∼18%) |
LGE (epicardial) involving anterior and lateral LV wall, no myocardial edema |
LGE, diffuse myocardial edema |
LGE (subepicardial) involving mid and apical LV free wall, myocardial edema, hyperemia |
Echocardiogram |
Normal |
Normal |
Borderline basal lateral and basal posterior strain |
Normal |
Normal |
Normal |
Mildly depressed RV and LV systolic function (LVEF 47%) |
ECG |
Atrioventricular dissociation with junctional escape rhythm, ST elevation |
ST segment elevation (diffuse) |
ST elevation (diffuse), T-wave abnormality |
ST elevation |
Sinus bradycardia, T-wave abnormality |
ST elevation (diffuse) |
ST elevation, low voltage of extremity leads |
Therapeutics: |
Oxygen supplementation |
None |
None |
None |
None |
None |
None |
LFNC |
Vasoactive medications or inotropic support |
None |
None |
None |
None |
None |
None |
None |
Antiinflammatory agents and other relevant medications |
NSAID, IVIg, IV methylprednisolone, PO prednisone, famotidine |
NSAID, colchicine, aspirin |
NSAID, famotidine |
NSAID, IVIg, IV methylprednisolone, PO prednisone |
NSAID, IVIg, IV methylprednisolone, PO prednisone, aspirin |
IVIg, PO prednisone |
NSAID, famotidine, furosemide |
Abbreviations: HHV-6, human herpesvirus-6; IgG, immunoglobulin G; IgM, immunoglobulin M; INR, international normalized ratio; IV, intravenous; LGE, late gadolinium enhancement; LFNC, low flow nasal cannula; LV, left ventricular; LVEF, left ventricular ejection fraction; PO, per os (oral); q12hr, every 12 hours; RF, regurgitant fraction; RV, right ventricular; —, not done.
|
Study Author Conclusions
|
Our case series has inherent limitations. We compiled cases through personal communications among colleagues rather than using a systematic surveillance system to identify cases. It was not possible to exclude all alternative etiologies including idiopathic and other infectious etiologies, and there was not a systematic diagnostic evaluation for other viral etiologies. Cardiac biopsy was not performed on any patients because they were all clinically stable during hospitalization. However, no patient had evidence of a preceding or concurrent symptomatic viral illness to implicate as an etiology of myocarditis, and the lack of eosinophilia dissuades a hypersensitivity reaction.
The pathophysiology of myocarditis in these patients is indeterminate, and we do not know if it is the same or different from classic myopericarditis or myopericarditis after other vaccines, associated with acute COVID-19, or with MIS-C. Given the nature of a case series, we cannot determine the incidence rate of myocarditis and myopericarditis after COVID-19 mRNA vaccination. Finally, a negative nucleocapsid antibody test result does not conclusively rule out the possibility of natural infection.
A series of U.S. cases of myocarditis and myopericarditis in adolescent male individuals occurred after the second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine. Fortunately, none of our patients was critically ill and each was discharged from the hospital. At present, there is no definite causal relationship between these cases and vaccine administration.
|